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Abstract
Although the rate of new HIV infections has been declining, AIDS continues to be one of the leading causes of 
death worldwide. The lack of an effective HIV vaccine makes it necessary to develop alternative strategies, such 
as the development of topical microbicides, to prevent transmission. Antimicrobial peptides represent promising 
microbicide candidates. Previously, we succeeded in enhancing the anti-HIV activities of several peptides that form 
helical structures based on the bioinformatic results learned from the antimicrobial peptide database. This study 
showed that Lys-to-Arg alterations also improved the HIV inhibitory activity of thanatin which is known to form a 
???????????????????????????????????????? ?????????????????????????????? ????????????????????????????? ?????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
thanatin-mimicking constructs are referred to as GLRC peptides since they are composed of only four amino acid 
residues G, L, R, and C. While GLRC-2, the peptide with a medium-sized loop structure, was most potent against 
HIV-1 and HSV-2, GLRC-3, with the small loop structure, was most potent against Escherichia coli K12. Thus, the 
??????????? ?????????????????? ?????????????????????????????? ????????? ????????? ????????????????????? ????????
antimicrobial activity against both viruses and bacteria. It appears that the high antiviral potency of GLRC-2 is 
related to high hydrophobicity, although a wide-range correlation is lacking. In addition, GLRC-2, which is more 
active against viruses, is also more resistant to the action of chymotrypsin. Therefore, GLRC-2, a novel peptide that 
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
point for additional rounds of peptide engineering.    
Keywords: Antimicrobial peptides; HIV-1; Peptide stability; Micro-
bicides
Introduction
     Since the report of the "rst human immunode"ciency virus (HIV) 
case in 1981, the acquired immunode"ciency syndrome (AIDS) has 
become the fourth leading cause of death worldwide. #e United Na-
tions estimates that there are now 40 million people living with HIV/
AIDS. #us, it is urgent to develop novel therapeutic and preventative 
agents to reduce the transmission of HIV. Because the majority of HIV 
infections are acquired through heterosexual intercourse, it would be 
helpful if measures can be taken to stop or prevent the sexual transmis-
sion of HIV [1,2]. 
We have been focusing on identifying potent anti-HIV candidates 
derived from naturally occurring antimicrobial peptides (AMPs). #ese 
peptides have been proven to have antimicrobial e$ects on a broad 
range of bacteria, viruses, fungi, and parasites [3-6]. Select amphibian 
and piscine AMPs are known to reduce infectivity of channel cat"sh 
virus (CCV), frog virus 3 (FV3), and HIV [7,8]. In addition, AMPs 
with anti-HIV activity have also been discovered from other sources, 
which include melittin and cecropin from insects [9], cathelicidins 
and defensins from mammals [5,10-13], and cyclotides (i.e. circular 
peptides) from plants [14]. We previously identi"ed the most potent as 
well as the minimal anti-HIV fragments within human cathelicidin LL-
37 [13]. A follow-up study showed that LL-37 fragments inhibited HIV 
reverse transcriptase in vitro [15]. It is also likely that the antiviral e$ect 
of vitamin D is associated with the expression of human LL-37 in vivo 
[16]. We also found that BMAP-18, a fragment derived from bovine 
cathelicidin BMAP-27, is a HIV-1 inhibitor (EC50 = 0.83 ?g/ml) with 
a therapeutic index (TI) of 24 [13]. To identify additional templates, 
we have evaluated 30 peptides selected from the antimicrobial peptide 
database [17,18]. #e results of that peptide screening led to the 
identi"cation of 10 HIV inhibitory peptides with EC50 values in the 
range of 1.0 to 10 ?g/ml [19]. #is study extends the results of our 
previous studies by evaluating AMPs with di$erent loop structures. 
#ese peptides were designed using GLR-19 as a template. GLR-19 
was previously de novo designed based on the antimicrobial peptide 
database [17,19]. We also compared the stability of these peptide 
sca$olds to the action of chymotrypsin. #e results of the current study 
are reported herein.   
Materials and Methods
Peptides
All the peptides were chemically synthesized using the solid-phase 
method and puri"ed by HPLC to >95% (Genemed Synthesis, Inc., TX).
Anti-HIV assays
Anti-HIV-1 cytopathic e$ect (CPE)-inhibition assays were 
performed as described [20]. In brief, serially diluted peptides were 
added to a 96-well round bottom microtiter plate in triplicate. CEM-
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SS cells at a concentration of 2.5 ? 103 cells per well and HIV-1IIIB 
at the appropriate pre-determined titer were sequentially added to 
the microtiter plate. #e cultures were incubated at 5% CO2/37°C for 
six days. Following the incubation, the microtiter plates were stained 
with XTT tetrazolium dye to evaluate the e'cacy and toxicity of the 
test compound(s). Using 4-parameter curve "tting, values of EC50 
(50% inhibition of virus replication), and TC
50
 (50% reduction in 
cell viability), as well as a therapeutic index (TI = TC
50
/EC
50
), were 
determined for each peptide. 
Antibacterial assays
#e antibacterial activity of the peptides was analyzed using the 
standard approach of microdilution [21]. #e bacterial strains used 
were Escherichia coli K12 and Bacillus subtilis. In brief, small bacterial 
cultures were grown overnight. Fresh cultures were inoculated with a 
small aliquot of the overnight culture and incubated at 37oC until the 
optical density A600 of the culture reached ~0.5. #e bacterial culture 
(90 ?l each) was then diluted to an A600 of 0.001 and partitioned into a 
96-well plate with ~105 colony-forming units (CFU) per well. #e cells 
were then treated with 10 ?l of the peptide at di$erent concentrations, 
allowing the minimum inhibitory concentration (MIC) measurement 
for each. #e assay was duplicated and repeated multiple times. #e 
plate was then further incubated at 37oC overnight (~16 hrs) and read 
at 630 nm on a ChroMate 4300 microplate reader (GMI, MN).
High performance liquid chromatography (HPLC)
#e retention time of the peptide was measured on a Waters HPLC 
system equipped with an analytical reverse-phase Waters symmetry 
C8 column (150 × 3.9 mm). #e peptide was eluted by a gradient of 
acetonitrile (containing 1% TFA) from 5% to 95% at a +ow rate of 1 ml/
min. #e peptide peak was detected by UV at 254 nm.  
Electrophoresis assays of peptide stability
Peptide (0.5 mM) and chymotrypsin (molar ratio 40:1) were mixed 
and incubated at 37oC in 10 mM PBS bu$er (pH 8.0). An aliquot 
(20 µl) of the reaction was taken at di$erent hours and immediately 
mixed with 10 µl of SDS loading bu$er to terminate the action of the 
protease. Aliquots of the reactions were subsequently analyzed using 
18% stacking tricine SDS-PAGE. #e bands were stained by Coomassie 
Brilliant Blue R250 (Fisher). Images of the gels were taken and digitized 
in Photoshop 6.0 for band quanti"cation. 
Results 
Engineering of HIV inhibitory peptides based on an AMP 
with a b-sheet structure  
Our previous studies focused on linear peptides from which several 
HIV inhibitory candidates have been identi"ed. #ose peptides such 
as the GI-20 and BMAP-18 have a tendency to form amphipathic 
helical structures, especially when in complex with membranes [21-
23]. In this study, BAMP-18 was included as a control and it showed 
a similar e'cacy in Table 1 as reported previously [13]. To expand 
the conformation space, we shi?ed our focus to AMPs with a ?-sheet 
structure. #anatin is a natural AMP isolated from the insect Podisus 
maculiventris (i.e., the spined soldier bug) [24]. #is peptide was 
chosen because it has a simple hairpin structure with a single disul"de 
bond (C11-C18) between the two strands (Figure 1A) [25]. Two 
derivatives of thanatin were obtained. In the structure-based peptide 
1 (SB1), the last residue Met of thanatin was substituted with Ile to 
reduce possible oxidation of the peptide. #is peptide demonstrated 
activity against HIV-1 but poor activity against HSV-2 (Table 1). To 
enhance the anti-HIV activity of SB1, residues K3, K4, and K17 were 
converted to arginines based on previous "ndings from the AMP 
database [17,18]. SB2, the arginine analog of SB1, indeed showed 
higher activity against HIV-1. However, these changes deprived SB1 of 
the weak activity against HSV-2 (Table 1). Since there was no increase 
in cytotoxicity, the reduced EC50 value of SB2 directly translated into a 
greater TI (Table 1). #e TI of SB2 reached 30, which is slightly greater 
than those (TI = 21-25) determined for GI-20 (derived from human 
LL-37), BMAP-18 (derived from cattle cathelicidin BMAP-27), and an 
arginine analog of dermaseptin S9 [13,19]. 
De novo design of peptides with various loop structures 
We designed additional peptides using GLR-19 as the starting 
sequence. #is peptide is a de novo designed peptide which is known 
to be inhibitory to HIV-1 [17,19]. We found that GLR-19 also showed 
antiviral activity against HSV-2 (Table 1). To mimic the hairpin 
structure of thanatin, we introduced a disul"de bond at di$erent 
positions within GLR-19 (Figure 1). In each case, the incorporation 
of a disul"de bond into GLR-19 was at the expense of two leucines, 
which were replaced by cysteines. Initially, a disul"de bond (yellow 
lines in Figure 1) was positioned between residues 2 and 18 (C2-C18) 
to generate a large loop structure. #is disul"de bond was shi?ed to 
generate additional peptides with a reduced loop size (Figure 1). We 
referred to these disul"de bond-linked peptides as GLRC peptides 
since their sequences are composed of only G, L, R and C amino acid 
residues. GLRC-1, the peptide with the large 17-residue loop, yielded 
an EC50 greater than 100 µg/ml, which was the highest concentration 
evaluated in antiviral assays [13]. GLRC-2, however, the peptide with 
a middle-sized 13-residue loop, demonstrated the highest potency 
(EC50 = 1.81 µg/ml). When the size of the loop was furthered reduced 
to obtain GLRC-3, antiviral activity was reduced. In parallel antiviral 
assays, GLRC-2 also showed the best activity against HSV-2 compared 
 
Figure 1: De novo design of novel anti-HIV peptides by mimicking the ?-hairpin 
structure of thanatin. (A) A ribbon view of the 3D structure of thanatin (PDB 
????????????????????????????????????????????????????????????????????????????????
Systematic construction of peptides with varying loops or scaffolds. The starting 
????????????????????????????????????????????????????????????????????????????????
natural antimicrobial peptides collected in the antimicrobial peptide database 
[17, 19]. For additional details on peptide design, see the text. Yellow bars rep-
??????????????????????????????????????????????????????????????????????????????
for each peptide fold (i.e. the EC50 value from Table 1) is given in parenthesis.
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to both GLRC-1 and GLRC-3 (Table 1). #ese results highlight the 
importance of the C4-C16 disul"de linkage in GLRC-2. Consistent 
with this observation, GLRC-4 was also determined to be inactive when 
two di$erent disul"de bonds (C2-C18 and C6-C14) were applied in 
the peptide. However, the GLRC peptides with disul"de bonds all had 
reduced activity against HSV-2 compared to the linear template GLR-
19 (Table 1). #e possibility that linear AMPs are generally more active 
than their disul"de counterparts against HSV-2 remains to be tested. 
Next, we further mimicked the sca$old of SB2 by removing either 
the N- or the C-terminal residues outside of the loop (Figure 1). When 
the C-terminal segment LLR was truncated, the resulting peptide 
GLRC-5 became inactive. In contrast, the peptide GLRC-6 remained 
active a?er the N-terminally exposed residues, GLR, of GLRC-2 were 
removed. Another peptide (GLRC-7) was obtained by removing 
both the N- and C-terminal segments outside of the loop of GLRC-
2. Like GLRC-5, GLRC-7 was inactive. #ese results suggest that the 
C-terminal LLR segment of GLRC-2 is important for anti-HIV activity. 
We also evaluated if the sequence of the central fragment between the 
two Cys residues of GLRC-2 played a role in antiviral activity. To 
address this question, we altered the sequence order without changing 
the amino acid composition. To our surprise, the resulting peptide 
GLRC-8 was found to be inactive (Table 2). We conclude that both the 
order of the central sequence and the C-terminal region of GLRC-2 
play an important role in HIV inhibition.    
Because these GLRC peptides are novel, we also evaluated their 
antibacterial activity using representative laboratory strains. Overall, 
these peptides showed poor activity against Gram-positive B. subtilis 
(Table 2). In the case of Gram-negative E. coli K12, the most active 
peptide (MIC = 7.5 µM) was GLRC-3, the peptide with the smallest 
loop (Figure 1). Peptides GLRC-1, GLRC-2, GLRC-6, and GLRC-8 
showed similar anti-E. coli activity (MIC = 30 µM), indicating that the 
N-terminal segment GLR of GLRC-2 is dispensable for antibacterial 
activity. Interestingly, the least active peptide was determined to be 
GLRC-7, the shortest GLRC peptide with a 13-residue loop structure. 
#us, the C-terminal segment of GLRC-2 appears to be important also 
for bactericidal activity. 
Peptide parameters that in"uence activity
To provide further insight into the antimicrobial activities of these 
peptide constructs, we measured the retention times of the GLRC 
peptides by reverse-phase HPLC (Table 2). #e retention time is 
related to peptide hydrophobicity [23]. Other parameters such as net 
charge, hydrophobic residues% (pho% in Table 3), and Boman index 
[18] (i.e. protein binding potential) [3] were also calculated for the 
Peptide Amino acid 
????????
# of
AA S-S bond
HIV-1IIIB in CEM-SS cells HSV-2MS in Vero cells
EC
50
a
(?g/ml) TC50(?g/ml) TI EC50(?g/ml) TC50(?g/ml) TI
BMAP-18
GRFKRFRKK
FKKLFKKIS
18 0.83 19.8 23.9 27.2 >100 >3.7
SB1
GSKKPVPIIYC
NRRTGKCQRI
21 C11-C18 13.1 >100 >7.6 64.9 >100 >1.5
SB2
GSRRPVPIIYC
NRRTGRCQRI
21 C11-C18 3.33 >100 >30 >100 >100 ---
GLK-19
GLKKLLGKLL 
KKLGKLLLK 
19 >47.5 25.1 <0.5 n.e.b n.e.
GLR-19
GLRRLLGRLL
RRLGRLLLR 
19 4.06 17.8 4.4 2.32 12.4 5.3
GLRC-1 GCRRLLGRLLRRLGRLLCR 19 C2-C18 >100 59.2 <1.0 30 >100 >3.3
GLRC-2 GLRCRLGRLLRRLGRCLLR 19 C4-C16 1.81 17.8 9.83 5.43 31.8 5.9
GLRC-3 GLRRLCGRLGRRLCRLLLR 19 C6-C14 6.37 18.5 2.9 15 62.3 4.2
GLRC-4 GCRRLCGRLGRRLCRLLCR 19
C2-C18
C6-C14
69.3 >100 >1.44 64.7 >100 >1.5
GLRC-5 GLRCRLGRLLRRLGRC 16 C4-C16 >100 59.5 <1.00 n.e. n.e.
GLRC-6 CRLGRLLRRLGRCLLR 16 C1-C13 7.72 41.9 5.43 n.e. n.e.
GLRC-7 CRLGRLLRRLGRC 13 C1-C13 >100 >100 --- n.e. n.e.
GLRC-8 GLRCLRLRGRLRLGRCLLR 19 C4-C16 >100 31 <1.00 n.e. n.e.
Table 1: Antiviral activities of de novo designed peptides. aAlthough not provided in the table, the standard error from multiple antiviral assays is on average less than 
10% of the respective mean EC50 or TC50 values. bn.e., not evaluated.
Peptide
 name
Net 
charge
# of
R or K
Pho%
HPLC
t
R
 (min)
Boman
index
E. coli
MIC (?M) B. subtilisMIC (?M)
GLK-19 7 7K 47 9.776 -0.43 10a n.e.b
GLR-19 7 7R 47 9.263 3.01 >120 n.e.
GLRC-1 7 7R 47 7.452 3.4 30 >120
GLRC-2 7 7R 47 12.344 3.4 30 >120
GLRC-3 7 7R 47 10.101 3.4 7.5 >120
GLRC-4 7 7R 47 9.601 3.78 60 >120
GLRC-5 7 6R 43 9.373 3.39 60 >120
GLRC-6 7 6R 50 9.395 3.47 30 60
GLRC-7 6 5R 46 8.734 3.88 120 >120
GLRC-8 8 7R 47 9.18 3.4 15-30 >120
Table 2: Effects of peptide scaffolds on their bacterial inhibitory activities. a. Data were taken from ref. [19]. bn.e., not evaluated.
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GRLC peptides using the prediction interface of the AMP database 
(http://aps.unmc.edu/AP/main.html) [18] and are included in Table 
3. While it is not obvious why GRLC-3 is most active against E. coli, 
the high potency of GLRC-2 against HIV-1 is likely to be due to high 
hydrophobicity of the peptide, which has the longest retention time 
(tR) (Table 2).  
Stability of the GLRC peptides to chymotrypsin
 We also compared the stability of the GLRC peptides to 
the action of proteases such as chymotrypsin. Figure 2 shows the 
percentage of intact peptide a?er protease treatment at 37oC for 4 
hrs. For comparison, SB1 was also tested and was found to have 23% 
intact peptide remaining at 4 hrs. Compared to SB1, the linear template 
GLR-19, with 15.5% intact peptide remaining, was less stable (Figure 
2). Restraining the GLR-19 polypeptide chain with disul"de bonds 
had a signi"cant impact on peptide stability. First, we determined that 
peptide stability was related to the loop size: GLRC-2 > GLRC-1 > 
GLRC-3 (Figure 1). #us, GLRC-2, with a medium-sized loop structure, 
acquired improved stability (>60% intact peptide) compared to SB1 
(23% intact peptide, Figure 2). #e stability of GLRC-2 increased by 
4.4 fold relative to GLR-19. Note that GLRC-4, with two disul"de bond 
patterns as in GLRC-1 (C2-C18) and GLRC-3 (C6-C14), did not gain 
additional stability to the protease, further indicating the importance 
of the C4-C16 disul"de bond. Second, although GLRC-2 and GLRC-8 
share the medium-sized loop, they had drastically di$erent stability. It 
is likely that the sequence order in the loop determines the extent of 
overall packing of the peptide chain. #ird, the segment outside of the 
loop appeared to be critical for GLRC-2 stability. In particular, removal 
of the N-terminal segment was detrimental, leading to complete 
degradation of the peptide in four hours. #e C-terminal segment was 
less important with about 50% of the peptide remaining at 4 hrs. #is 
is in contrast to the importance of the C-terminal segment for anti-
HIV activity. Nevertheless, it is interesting to note that GLRC-2, which 
demonstrated the greatest activity against HIV-1 (Table 1), was also the 
most stable to protease compared to the other GLRC peptides (Figure 
2). 
Discussion
In order to identify AMP candidates as lead products for the 
development of topical microbicides, we have continued our e$orts to 
search for potent anti-HIV peptides. In our previous studies [13,19], 
di$erent engineering strategies were adopted. #ese included database 
screening, sequence shu@ing, and database-aided antiviral activity 
enhancement [26]. A?er activity enhancement, several anti-HIV 
peptides in the helical family were obtained with TIs >20. #e current 
study identi"ed a β-hairpin peptide SB2 with a TI = 30 by using the 
same Lys-to-Arg mutational strategy [19]. It seemed that this strategy 
might be applicable to the improvement of anti-HIV activity of AMPs 
with di$erent structural sca$olds. 
#e establishment of the antimicrobial peptide database facilitated 
bioinformatic analysis of natural AMPs from a de"ned family or 
source [17,18]. For example, the frequently occurring residues from 
amphibian AMPs were identi"ed as G, L, A, and K. #e peptide, GLK-
19 (Table 1), was previously de novo designed using only G, L, and 
K residues. GLK-19 was found to be active against Gram-negative E. 
coli but not Gram-positive Staphylococcus aureus [17]. Because only 
AMPs with antiviral activity are known to have an R/K ratio greater 
than one in our database, GLR-19 was designed by converting all 
lysines to arginines. While GLK-19 showed no HIV-1 inhibitory 
activity at a peptide concentration of 100 ?g/ml, GLR-19 was found to 
be active against both HIV-1 [19] and HSV-2 (Table 1). In this study, 
we have designed a series of peptides with loop structures based on 
the linear peptide GLR-19 (Figure 1). We demonstrated that the anti-
HIV activity of the peptide was also dependent on the loop size. While 
GLRC-2 with a medium 13-residue loop was the most potent against 
HIV-1, GLRC-3 with a small 9-residue loop was the most active against 
E. coli. It is evident that the optimal design of an antimicrobial peptide 
is microbe dependent. 
Because these de novo designed peptides have a relatively simple 
amino acid composition, we also investigated possible structure-
activity correlations. In the case of E. coli, there was no clear 
correlation between peptide activity and any physical parameters 
listed in Table 2, including net charge, the number of Lys or Arg, 
percentage of hydrophobic residues, Boman index [18] (or protein 
binding potential [3], and HPLC retention time (hydrophobicity). For 
the GLRC peptides, however, we noticed that GLRC-7, with a minimal 
number of positively charged residues, was the least active against 
Gram-negative E. coli, whereas GLRC-6, with the highest hydrophobic 
content (50%), is the only peptide that was moderately active against 
Gram-positive B. subtilis (Table 2). #ese observations are in line with 
the current knowledge on AMPs in general [26]. It was also di'cult 
to "nd any correlation between anti-HIV activity and these peptide 
properties. #ese observations indicate that multiple factors determine 
the biological activity of these AMPs. However, for the three most 
active GLRC peptides, their HIV inhibitory activities were found to 
be proportional to hydrophobicity as measured by HPLC (Tables 1 
& 2). In particular, the higher activity of GLRC-2 corresponded with 
its higher hydrophobicity, although this correlation could not be 
extended to all the peptides in Table 1. Craik and colleagues noticed 
that, among the HIV inhibitory plant cyclotides, cycloviolacin Y5, 
isolated from the traditional Chinese herb Viola yedoensis, was the 
most hydrophobic and also the most potent [27]. #ey proposed that 
cycloviolacin Y5 acted on viral membranes. Whether GLRC-2 acts by 
the same mechanism remains to be established. Interestingly, GLRC-2 
also showed higher stability to the action of chymotrypsin compared to 
the other members of the GLRC peptide family as well as to its linear 
template GLR-19 (Figure 2). 
In summary, we have demonstrated the enhancement of anti-HIV 
activity of linear AMPs that tend to form amphipathic helical structures 
using the Lys-to-Arg mutational strategy [19]. We illustrated here that 
anti-HIV activity of SB1, a thanatin analog with a ?-hairpin fold, could 
also be improved by the same strategy [19]. Our current study has 
 
Figure 2: Stability comparison of the de novo designed GLRC peptides after 
incubation with chymotrypsin at 37oC for 4 hrs (see Methods). Both SB1 and 
GLR-19 are included for comparison. The percentages of uncleaved peptides 
are represented by the height of the bars and also indicated at the top of the 
bars.  For example, GLRC-5 had ~50% intact peptide remaining after 4 hrs.
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expanded our knowledge of the relationship between AMP structure 
and anti-HIV activity. In addition to peptide length, sequence order, 
charge, amino acid type, and structure [13,19], peptide sca$olds or 
folds also play a pivotal role (Tables 1 & 2). Evaluation of peptides with 
varying sca$olds is important because of their di$erent susceptibilities 
to proteases (Figure 2). #is study led to the discovery of a novel 
peptide GLRC-2 that demonstrated both greater anti-HIV activity 
and greater stability to chymotrypsin over the GLR-19 template. #ese 
results should be helpful for our future design of highly potent anti-
HIV peptides with desired stability. In addition, our studies may also 
contribute to the identi"cation of novel antimicrobial agents with 
activity against other viral and bacterial pathogens.  
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